Ganciclovir is a medication used to treat infections caused by the herpes virus, like cytomegalovirus (CMV). It's often used in people with weakened immune systems, such as those with AIDS. It works by stopping the virus from multiplying. It's usually given by injection.
Every report comes from a Lived member, sent anonymously.
Have you tried Ganciclovir for CMV?
Ganciclovir is an antiviral medicine used mainly against cytomegalovirus (CMV), a common herpes-family virus. Most people carry CMV quietly for life, but when the immune system is weakened it can cause serious disease. Ganciclovir injection is approved to treat CMV retinitis, an infection of the light-sensing layer at the back of the eye that can cause blindness, in adults with weakened immunity, including people with AIDS. It is also approved to prevent CMV disease in adult organ transplant recipients who are at risk, and transplant teams use it to treat active CMV infections as well. The original brand, Cytovene, is no longer sold in the US; the injection is now available as a generic. A separate eye gel, Zirgan, contains a small dose of ganciclovir and treats herpes simplex ulcers on the surface of the eye in adults and children 2 and older. It acts only on the eye, so most of what follows concerns the injection. Valganciclovir (Valcyte and generics) is a pill or liquid that the body converts into ganciclovir. For CMV disease that is not life- or sight-threatening, transplant guidelines generally prefer it when a person can take it by mouth, because it avoids an IV line and can shorten or prevent a hospital stay. IV ganciclovir is preferred for the most severe infections, when getting enough drug into the body quickly matters most.
To multiply, CMV has to copy its DNA. Ganciclovir is built to resemble one of the natural building blocks of DNA. Inside a CMV-infected cell, a viral enzyme activates the drug, and the activated form then jams the enzyme the virus uses to copy its DNA. Because activation depends mostly on that viral enzyme, the drug concentrates its effect in infected cells. Ganciclovir stops the virus from multiplying rather than destroying it outright, so the immune system still has to bring the infection under control. The drug also affects rapidly dividing human cells, especially in the bone marrow, which explains its most important side effects.
Ganciclovir injection is given only into a vein, as a slow infusion over one hour by a nurse or other healthcare provider, usually in a hospital or infusion center. It is never given as a quick push or into a muscle, because high peak levels and the drug's strong alkalinity can cause harm. Treatment usually starts with an induction phase, an intensive stage with doses every 12 hours for one to three weeks, followed by a once-daily maintenance phase. After a transplant, prevention typically continues until about 100 to 120 days after surgery. Doses are calculated from body weight, and because the kidneys clear the drug, the dose is lowered when kidney function is reduced. Blood counts and kidney tests are checked frequently throughout treatment, and people who can become pregnant need a pregnancy test before starting. Zirgan eye gel is applied as one drop in the affected eye five times a day until the ulcer heals, then three times a day for seven more days.
Fever, diarrhea, nausea, loss of appetite, headache, weakness and sweating are among the most common effects. Because many people receiving ganciclovir are already seriously ill, it can be hard to tell which symptoms come from the drug and which from the underlying illness. Some people develop numbness or tingling in the hands or feet, or pain and swelling where the infusion goes in. An IV line itself can become infected. The most important side effect is a drop in blood counts. Ganciclovir can lower white blood cells, which fight infection, red blood cells, which carry oxygen, and platelets, which help blood clot. This most often appears in the first two weeks but can happen at any point, and counts usually begin to recover within a few days of stopping. Regular blood tests catch most of these drops early. Call the care team right away for fever, chills, sore throat or other signs of infection; unusual bleeding or bruising; or new paleness, unusual tiredness, a racing heartbeat or shortness of breath. Also contact the team promptly about any change in vision, a noticeable change in how much you urinate, or new swelling of the face, hands, legs or ankles, which can point to kidney problems. Zirgan eye gel mainly causes temporary blurred vision and eye irritation.
Ganciclovir carries the FDA's most serious type of warning, a boxed warning, for four reasons: low blood counts, harm to fertility, harm to a developing baby, and possible cancer risk. In animals it caused birth defects and cancers, and in men it can reduce sperm production, possibly permanently; it may also reduce fertility in women. People hoping to have children later may want to discuss fertility options before treatment when time allows. Anyone who can become pregnant should use effective birth control during treatment and for at least 30 days afterward. Men should use condoms during treatment and for at least 90 days afterward. Breastfeeding is not recommended during treatment. These warnings come from the injection and also apply to valganciclovir, not to the eye gel. Many medicines common in transplant and HIV care add to ganciclovir's effects on the bone marrow or kidneys. Examples include mycophenolate and tacrolimus, which are anti-rejection drugs; cyclosporine, another anti-rejection drug; amphotericin B, an antifungal; and trimethoprim-sulfamethoxazole, an antibiotic. These are often still used together, with closer blood and kidney monitoring. Seizures have been reported when ganciclovir is combined with imipenem-cilastatin, an IV antibiotic, so that pairing is generally avoided. People who have had a serious allergic reaction to ganciclovir or valganciclovir should not receive either.
For CMV retinitis, the goal is to stop the infection from spreading across the retina and destroying more vision, and frequent eye examinations during treatment track whether the infection is controlled. For transplant recipients, the team usually measures the amount of CMV in the blood each week and continues treatment doses until the level falls below a set threshold; stopping too early raises the risk of the virus returning or becoming resistant. Over the course of treatment, many people move from IV ganciclovir to oral valganciclovir once they are stable enough, which can allow treatment at home. If blood counts fall, the team may pause other bone-marrow-suppressing medicines, give a growth factor that boosts white cell production, or switch to another antiviral. The strength of the immune system also matters: in transplant recipients, easing anti-rejection medicines when it is safe to do so can help the body clear CMV.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Ganciclovir, what you've noticed, or ask the community a question.